Physician profile
Patrick F Dial
NPI 1790730851
$1,134.47
in general payments reported to CMS, 2019-2025
28 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $124 · 2021: $90.18 · 2022: $249 · 2023: $218 · 2024: $103 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $224.37 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Baxter Healthcare | $139.15 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.71 | 2022-2023 | Gattex |
| Regeneron Healthcare Solutions, INC. | $53.72 | 2023 | Libtayo |
| Merck Sharp & Dohme LLC | $53.30 | 2019-2022 | |
| Abbott Laboratories | $51.56 | 2022-2025 | Eterna |
| Zimvie INC. | $47.40 | 2022-2023 | |
| Medtronic, INC. | $47.01 | 2021-2024 | Ligasure |
| Si-Bone, INC. | $46.07 | 2021-2024 | |
| Kerecis Limited | $45.52 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Kci USA, INC. | $35.10 | 2021-2023 | V.A.C. Veraflo |
| Genzyme Corporation | $33.38 | 2019-2022 | |
| Davol INC. | $28.62 | 2019-2020 | |
| Merit Medical Systems INC | $27.28 | 2020 | |
| Mimedx Group, INC. | $23.67 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $22.81 | 2022 | |
| Medical Device Business Services, INC. | $22.65 | 2025 | Echelon; Endopath |
| Mallinckrodt Hospital Products INC. | $18.12 | 2021 | |
| Shire North American Group INC | $18.11 | 2019 | |
| Portola Pharmaceuticals, LLC | $17.29 | 2019 | |
| Vericel Corporation | $17.17 | 2022 | |
| Bioventus LLC | $16.85 | 2024 | Durolane |
| Ethicon US, LLC | $16.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.87 | 2022 | |
| Hologic Sales and Service, LLC | $15.76 | 2025 | Sentimag |
| Integra Lifesciences Corporation | $15.27 | 2021 | |
| W. L. Gore & Associates, INC. | $14.82 | 2021 | |
| Focal Therapeutics, INC. | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.